PPI

Pantoprazole Sodium Hydrate (BY1023 (sodium hydrate)) is a proton pump inhibitor drug, used for short-term treatment of erosion and ulceration of the esophagus caused by gastroesophageal reflux disease.

Pantoprazole (BY1023) is a proton pump inhibitor used for short-term treatment of erosion and ulceration of the esophagus caused by gastroesophageal reflux disease.

Pantoprazole sodium (Pantecta) is the sodium salt form of a substituted benzimidazole with proton pump inhibitor activity. Pantoprazole sodium is a lipophilic, weak base that crosses the parietal cell membrane and enters the acidic parietal cell canaliculus where it becomes protonated, producing the active metabolite sulfenamide, which forms an irreversible covalent bond with two sites of the H+/K+-ATPase enzyme located on the gastric parietal cell, thereby inhibiting both basal and stimulated gastric acid production.

IGS-1.76 exhibits pronounced affinity towards hNCS-1 and effectively modulates the interaction between hNCS-1 and Ric8a. Moreover, IGS-1.76 proficiently inhibits the complex formed by human NCS-1 and Ric8a.

IPR-803 is an effective inhibitor of the uPAR·uPA protein-protein interaction (PPI) with anti-tumor activity. IPR-803 binds directly to uPAR with a Ki of 0.2 μM.

SU3327 (halicin) is a potent, selective and substrate-competitive inhibitor of JNK(IC50 of 0.7 μM).

Rabeprazole sodium (Habeprazole Sodium) is a 4-(3-methoxypropoxy)-3-methylpyridinyl derivative of timoprazole that is used in the therapy of stomach ulcers and Zollinger-Ellison syndrome. The drug inhibits H(+)-K(+)-exchanging ATPase which is found in gastric parietal cells.

BMS-8 is a novel inhibitor of the PD-1/PD-L1 interaction (IC50: 7.2 μM) by binding directly to PD-L1 and inducing the formation of PD-L1 homodimers.

M2I-1 a small Mad2 inhibitor-1. the first small molecule inhibitor targeting the binding of Mad2 to Cdc20, an essential proteinprotein interaction (PPI) within the SAC. It can disturbs conformational dynamics of Mad2 critical for complex formation with Cd

MI-136 inhibits expression of androgen receptor (AR) target genes that DHT induced.

T-1101 tosylate (TAI-95 tosylate) is a Hec1/Nek2 inhibitor with antitumor activity.

TED-347 is an irreversible and covalent inhibitor of TEAD4-Yap1 protein-protein interaction(EC50 of 5.9 μM), and inhibits glioblastoma cell viability.

HIV-1 Nef-IN-1 is an inhibitor of the HIV-1 Nef protein, effectively competing for Nef-SH3Hck interactions (Kd: 6.7 μM).

SORT-PGRN interaction inhibitor 1 is a potent inhibitor of the sortilin-progranulin interaction, with an IC50 of 2 μM.

PPI-1019 is an APP (β-amyloid A4) inhibitor for the treatment of neurological disorders and the study of Alzheimer's disease (AD).

ATG5-PPI Inhibitor 17a is a potent inhibitor of ATG5-ATG16L1 protein-protein interaction (Kd=4.8 μM). It blocks autophagy flux by preventing complex formation.

ATG5-PPI Inhibitor 17b has a core structure of (E)-3-(2-furylmethylene)-2-pyrrolidinone and blocks the interactions between ATG5–ATG16L1 and ATG5–TECAIR in in vitro binding assays, with IC₅₀ values of 27.43 μM and 14.88 μM, respectively.

ATG5-PPI Inhibitor 17c has a core structure of (E)-3-(2-furylmethylene)-2-pyrrolidinone and blocks the interactions between ATG5–ATG16L1 and ATG5–TECAIR in in vitro binding assays, with IC₅₀ values of 12.78 μM and 12 μM, respectively.

ATG5-PPI Inhibitor 17e has a core structure of (E)-3-(2-furanmethylene)-2-pyrrolidone. In in vitro binding assays, this inhibitor blocks the interactions between ATG5 and ATG16L1, as well as between ATG5 and TECAIR, with an IC50 value of >33 μM for both interactions.

ATG5-PPI Inhibitor 17g is an autophagy inhibitor targeting the ATG5-ATG16L1 interaction (IC50 = 3.9 μM). It disrupts autophagy flux to inhibit vesicle expansion in cancer and inflammation research.

ATG5-PPI Inhibitor 17h features a core structure of (E)-3-(2-furfurylmethylene)-2-pyrrolidone, and it blocks the interactions between ATG5-ATG16L1 and ATG5-TECAIR in in vitro binding assays with an IC₅₀ of >33 μM for both.

ATG5-PPI Inhibitor 27e has a core structure of (E)-3-(2-furfurylmethylene)-2-pyrrolidone, and it blocks the interactions between ATG5-ATG16L1 and ATG5-TECAIR in in vitro binding assays with IC₅₀ values of >33 μM and 17.26 μM, respectively.

ATG5-PPI Inhibitor 27g has an (E)-3-(2-furylmethylene)-2-pyrrolidone core structure and blocks the interactions between ATG5‑ATG16L1 and ATG5‑TECAIR in in vitro binding assays, with IC50 values of 25 μM and 16 μM, respectively.

ATG5-PPI Inhibitor 27a has a core structure of (E)-3-(2-furylmethylene)-2-pyrrolidone and blocks the interactions between ATG5-ATG16L1 and ATG5-TECAIR in in vitro binding assays, with IC50 values of 2.29 μM and 3.68 μM, respectively.